

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



MARIZYME INC. Rank 326 of 446

The relative strengths and weaknesses of MARIZYME INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 424% points. The greatest weakness of MARIZYME INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 70% points below the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 1,955 |
| Cost of Goods Sold | 54 |
| Intangible Assets | 34,866 |
| Liabilities, Current | 2,922 |
| Liabilities, Non-Current | 18,344 |
| Other Assets | 1,854 |
| Other Compr. Net Income | 0 |
| Other Expenses | 33,524 |
| Other Liabilities | 0 |
| Other Net Income | -842 |
| Other Revenues | 233 |
| Property and Equipment | 13 |
| Research and Development | 3,979 |
| Selling, General and Administrative Expense | 0 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 38,688 |
| Liabilities | 21,266 |
| Expenses | 37,557 |
| Revenues | 233 |
| Stockholders Equity | 17,422 |
| Net Income | -38,166 |
| Comprehensive Net Income | -38,166 |
| Economic Capital Ratio | -27% |

